Effects of phytoestrogen supplementation in postmenopausal women with dry eye syndrome: a randomized clinical trial

ABSTRACT Objective To evaluate the correlation between tear osmolarity and blood levels of 17-β estradiol, estrone, and testosterone in postmenopausal women with dry eye syndrome, and to assess the efficacy and safety of oral supplementation with phytoestrogens, lipoic acid, and eicosapentaenoic aci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian journal of ophthalmology 2012-12, Vol.47 (6), p.489-492
Hauptverfasser: Scuderi, Gianluca, MD, Contestabile, Maria Teresa, MD, Gagliano, Caterina, MD, Iacovello, Daniela, MD, Scuderi, Luca, MD, Avitabile, Teresio, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Objective To evaluate the correlation between tear osmolarity and blood levels of 17-β estradiol, estrone, and testosterone in postmenopausal women with dry eye syndrome, and to assess the efficacy and safety of oral supplementation with phytoestrogens, lipoic acid, and eicosapentaenoic acid in this population. Design Cross-sectional study including 66 postmenopausal women with dry eye syndrome. Methods Sixty-six postmenopausal women with dry eye syndrome were enrolled in a randomized, double-blind, placebo-controlled, crossover study. Patients were divided into 2 groups (groups A and B) and treated, respectively, with phytoestrogen (Bioos, Montegiorgio, Italy) tablets or placebo tablets for 30 days. The 2 treatment periods were separated by a 30-day washout. Patients were examined on days 0 and 30 of each period. Assessments included blood levels of sex hormones, the Schirmer test for tear production, and measurement of tear osmolarity and tear film break-up time. Results At baseline, all patients had low sex hormone levels, which were correlated with high tear film osmolarity values ( r = −0.59,−0.61,−0.58, respectively). After 30 days of therapy, the group treated with Lacrisek® (Bioos) had significantly decreased tear osmolarity ( P
ISSN:0008-4182
1715-3360
DOI:10.1016/j.jcjo.2012.08.019